Phase 1 CD-19 specific third generation CAR T cell study data supports use of BioOra’s automated manufacture for phase 2
Results from 25 patients with relapsed or refractory B-cell non-Hodgkin lymphomas on ENABLE phase 1 safety trial presented at ASH 2023. • No severe (grade = 3) cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade.